PubRank

Lajos Pusztai

Author PubWeight™ 327.81‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 2006 30.90
2 Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008 11.03
3 Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005 9.70
4 Gene-expression signatures in breast cancer. N Engl J Med 2009 9.23
5 An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008 8.12
6 Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013 7.97
7 Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005 7.77
8 Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012 7.31
9 Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006 7.24
10 The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol 2010 7.08
11 Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007 7.00
12 The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009 6.00
13 A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 2011 4.63
14 A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer. N Engl J Med 2015 4.07
15 Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005 4.03
16 Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005 3.83
17 Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007 3.62
18 Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 2011 3.60
19 Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 2012 3.38
20 Concern The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003 3.36
21 Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. J Natl Cancer Inst 2013 3.35
22 Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol 2012 2.98
23 Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol 2010 2.91
24 Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol 2007 2.90
25 PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A 2010 2.79
26 Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002 2.75
27 Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol 2005 2.69
28 Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 2009 2.49
29 A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res 2011 2.26
30 Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res 2010 2.26
31 Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 2003 2.26
32 Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol 2007 2.19
33 Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst 2010 2.16
34 Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A 2005 2.16
35 Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J 2003 2.11
36 Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 2008 2.10
37 Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer 2003 2.01
38 The bimodality index: a criterion for discovering and ranking bimodal signatures from cancer gene expression profiling data. Cancer Inform 2009 1.98
39 Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol 2009 1.93
40 Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 2011 1.90
41 Challenges translating breast cancer gene signatures into the clinic. Nat Rev Clin Oncol 2011 1.86
42 Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 2011 1.83
43 Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res 2010 1.81
44 Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol 2011 1.79
45 Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics 2004 1.76
46 Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010 1.70
47 Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. J Clin Oncol 2010 1.63
48 Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncol 2010 1.57
49 Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 2011 1.53
50 Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol 2011 1.52
51 Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res 2007 1.52
52 HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Res Treat 2007 1.47
53 Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 2010 1.44
54 Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer. Ann Surg Oncol 2011 1.44
55 Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis. Cancer Res 2009 1.43
56 Effects of tissue handling on RNA integrity and microarray measurements from resected breast cancers. J Natl Cancer Inst 2011 1.38
57 Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer 2010 1.34
58 Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis. J Clin Oncol 2008 1.33
59 Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics 2011 1.32
60 Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer 2004 1.30
61 Standardizing slide-based assays in breast cancer: hormone receptors, HER2, and sentinel lymph nodes. Clin Cancer Res 2007 1.28
62 Biomarker studies: a call for a comprehensive biomarker study registry. Nat Rev Clin Oncol 2011 1.26
63 Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res Treat 2012 1.26
64 Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines. Breast Cancer Res Treat 2009 1.25
65 Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. Nat Clin Pract Oncol 2006 1.24
66 Targeted therapies for cancer 2004. Am J Clin Pathol 2004 1.23
67 Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer 2004 1.22
68 Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. Breast Cancer Res Treat 2005 1.20
69 Primary systemic chemotherapy of invasive lobular carcinoma of the breast. Lancet Oncol 2007 1.20
70 Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Res Treat 2010 1.19
71 Research issues affecting preoperative systemic therapy for operable breast cancer. J Clin Oncol 2008 1.18
72 Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer. Oncologist 2012 1.18
73 Higher parity and shorter breastfeeding duration: association with triple-negative phenotype of breast cancer. Cancer 2010 1.18
74 Unvalidated antibodies and misleading results. Breast Cancer Res Treat 2014 1.17
75 Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation. Eur J Cancer 2011 1.16
76 Multigene prognostic tests in breast cancer: past, present, future. Breast Cancer Res 2015 1.16
77 Evaluation of biological pathways involved in chemotherapy response in breast cancer. Breast Cancer Res 2008 1.15
78 Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα- breast cancer. Proc Natl Acad Sci U S A 2012 1.14
79 The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. Clin Cancer Res 2005 1.12
80 Breast cancer biomarkers and molecular medicine. Expert Rev Mol Diagn 2003 1.12
81 Comparison of the predictive accuracy of DNA array-based multigene classifiers across cDNA arrays and Affymetrix GeneChips. J Mol Diagn 2005 1.11
82 Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer. J Clin Oncol 2010 1.09
83 The role of tumor initiating cells in drug resistance of breast cancer: Implications for future therapeutic approaches. Drug Resist Updat 2010 1.08
84 Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J 2002 1.07
85 Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer. Cancer 2006 1.06
86 CXCR4 expression in early breast cancer and risk of distant recurrence. Oncologist 2009 1.05
87 Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. Breast Cancer Res Treat 2011 1.05
88 DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes. Oncologist 2013 1.04
89 Distinct tumor protein p53 mutants in breast cancer subgroups. Int J Cancer 2012 1.04
90 Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures. PLoS One 2011 1.03
91 Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg 2006 1.03
92 PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer. Breast Cancer Res 2008 1.02
93 Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer. Clin Cancer Res 2003 1.02
94 Biomarker analysis of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or Paclitaxel in early-stage breast cancer. Clin Cancer Res 2013 1.01
95 Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer. Clin Cancer Res 2012 1.00
96 Use of standard markers and incorporation of molecular markers into breast cancer therapy: Consensus recommendations from an International Expert Panel. Cancer 2010 0.99
97 Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol 2003 0.97
98 Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. Oncologist 2010 0.97
99 Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. Cancer 2007 0.97
100 High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients. Breast Cancer Res Treat 2012 0.97
101 Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. Cancer Res 2010 0.96
102 HER-2/neu testing in breast cancer. Am J Clin Pathol 2003 0.95
103 Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer. Breast Cancer Res 2012 0.95
104 Thirty-gene pharmacogenomic test correlates with residual cancer burden after preoperative chemotherapy for breast cancer. Clin Cancer Res 2007 0.95
105 Breast cancer biomarkers. Adv Clin Chem 2005 0.94
106 Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. J Clin Oncol 2012 0.93
107 A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice. Oncologist 2014 0.93
108 Stability of estrogen receptor status in breast carcinoma: a comparison between primary and metastatic tumors with regard to disease course and intervening systemic therapy. Cancer 2010 0.93
109 Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers. Breast Cancer Res 2013 0.92
110 Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy. Cancer 2005 0.92
111 Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer 2003 0.92
112 Reproducibility of gene expression signature-based predictions in replicate experiments. Clin Cancer Res 2006 0.92
113 Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers. Clin Cancer Res 2011 0.92
114 CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. Breast Cancer Res 2007 0.91
115 Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate. Breast Cancer Res Treat 2009 0.90
116 Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential. Breast Cancer Res 2014 0.90
117 RefSeq refinements of UniGene-based gene matching improve the correlation of expression measurements between two microarray platforms. Appl Bioinformatics 2006 0.90
118 Anatomy and biology: two complementary sides of breast cancer prognostication. J Clin Oncol 2011 0.90
119 Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers. Breast Cancer Res Treat 2013 0.90
120 Predicting prognosis of breast cancer with gene signatures: are we lost in a sea of data? Genome Med 2010 0.89
121 Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys 2004 0.89
122 Cell line derived multi-gene predictor of pathologic response to neoadjuvant chemotherapy in breast cancer: a validation study on US Oncology 02-103 clinical trial. BMC Med Genomics 2012 0.88
123 Breast cancer biomarkers and molecular medicine: part II. Expert Rev Mol Diagn 2004 0.88
124 Gene expression profiling of primary breast cancer. Curr Oncol Rep 2005 0.87
125 DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: current data and issues on study design. Biochim Biophys Acta 2006 0.86
126 Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers. Breast Cancer Res 2013 0.86
127 Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma. Cancer 2004 0.86
128 A systematic evaluation of multi-gene predictors for the pathological response of breast cancer patients to chemotherapy. PLoS One 2012 0.86
129 Lack of sufficiently strong informative features limits the potential of gene expression analysis as predictive tool for many clinical classification problems. BMC Bioinformatics 2011 0.86
130 Maximizing biomarker discovery by minimizing gene signatures. BMC Genomics 2011 0.86
131 First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations. Breast Cancer Res Treat 2011 0.86
132 Pharmacogenomics and clinical biomarkers in drug discovery and development. Am J Clin Pathol 2005 0.86
133 Development of candidate genomic markers to select breast cancer patients for dasatinib therapy. Mol Cancer Ther 2010 0.85
134 Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker. Oncologist 2013 0.84
135 Prediction of the outcome of preoperative chemotherapy in breast cancer using DNA probes that provide information on both complete and incomplete responses. BMC Bioinformatics 2008 0.84
136 Direct comparison of logistic regression and recursive partitioning to predict chemotherapy response of breast cancer based on clinical pathological variables. Breast Cancer Res Treat 2009 0.84
137 Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Res Treat 2012 0.84
138 Perspectives and challenges of clinical pharmacogenomics in cancer. Pharmacogenomics 2004 0.83
139 Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2-positive breast cancer using an LC-MALDI-TOF/MS procedure. Proteomics 2010 0.83
140 Improving patient care through molecular diagnostics. Semin Oncol 2004 0.83
141 Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer 2006 0.83
142 Effect of CYP2D6 polymorphisms on breast cancer recurrence. Cancer 2011 0.83
143 The Influence of Host Factors on the Prognosis of Breast Cancer: Stroma and Immune Cell Components as Cancer Biomarkers. Curr Cancer Drug Targets 2015 0.83
144 USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancer. Cancer J 2013 0.82
145 TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase. Cancer Res 2013 0.82
146 Influence of genomics on adjuvant treatments for pre-invasive and invasive breast cancer. Breast 2013 0.82
147 Adjuvant therapy in stage I carcinoma of the breast: the influence of multigene analyses and molecular phenotyping. Cancer 2012 0.81
148 Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response. BMC Bioinformatics 2011 0.81
149 Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes. Breast Cancer Res Treat 2012 0.81
150 Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types. Lancet Oncol 2011 0.81
151 Developing safety criteria for introducing new agents into neoadjuvant trials. Clin Cancer Res 2013 0.80
152 Heterogeneity of breast cancer among patients and implications for patient selection for adjuvant chemotherapy. Pharm Res 2006 0.80
153 Advances in translational research in breast cancer; a bridge to future therapies. Eur J Cancer 2008 0.80
154 Maximum predictive power of the microarray-based models for clinical outcomes is limited by correlation between endpoint and gene expression profile. BMC Genomics 2011 0.80
155 Dynamic classification using case-specific training cohorts outperforms static gene expression signatures in breast cancer. Int J Cancer 2014 0.80
156 A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade-2, ER-positive breast cancers into low- and high-risk prognostic categories. Breast Cancer Res Treat 2013 0.80
157 Adjuvant therapy in stage I carcinoma of the breast: the influence of multigene analyses and molecular phenotyping. Breast J 2012 0.79
158 Novel functional assay for spindle-assembly checkpoint by cyclin-dependent kinase activity to predict taxane chemosensitivity in breast tumor patient. J Cancer 2013 0.79
159 Optimizing outcomes in HER2-positive breast cancer: the molecular rationale. Oncology (Williston Park) 2005 0.78
160 Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypes. Cancer Epidemiol Biomarkers Prev 2013 0.78
161 Pharmacogenomics. Adv Anat Pathol 2004 0.78
162 Gene-expression microarrays provide new prognostic and predictive tests for breast cancer. Pharmacogenomics 2007 0.78
163 Statistical measures of transcriptional diversity capture genomic heterogeneity of cancer. BMC Genomics 2014 0.77
164 Molecular profiling contributes more than routine histology and immonohistochemistry to breast cancer diagnostics. Breast Cancer Res 2010 0.77
165 Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancers. Breast Cancer Res Treat 2015 0.77
166 Combined analysis of gene expression, DNA copy number, and mutation profiling data to display biological process anomalies in individual breast cancers. Breast Cancer Res Treat 2014 0.77
167 A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer. Breast Cancer Res Treat 2015 0.76
168 Metastatic gene signatures and emerging novel prognostic tests in the management of early stage breast cancer. Clin Exp Metastasis 2009 0.76
169 DCIS of the breast: a look towards discovery and advancements in the field. Ann Surg Oncol 2007 0.75
170 Are short-term or long-term recurrence rates more important in breast cancer screening? Ann Intern Med 2008 0.75
171 Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: a pooled analysis of four randomized trials. Oncologist 2010 0.75
172 Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer. Eur J Cancer Prev 2016 0.75
173 Bayesian mixture models for assessment of gene differential behaviour and prediction of pCR through the integration of copy number and gene expression data. PLoS One 2013 0.75
174 Economic Impact of Routine Cavity Margins Versus Standard Partial Mastectomy in Breast Cancer Patients: Results of a Randomized Controlled Trial. Ann Surg 2017 0.75
175 Building networks with microarray data. Methods Mol Biol 2010 0.75
176 Do pharmacogenomic tests provide value to policy makers? Pharmacoeconomics 2006 0.75
177 Erratum: Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations. Nat Commun 2017 0.75
178 New Therapeutic Strategies for Triple-Negative Breast Cancer. Oncology (Williston Park) 2017 0.75
179 Optimizing outcomes in HER2-positive breast cancer: the molecular rationale. Oncology (Williston Park) 2005 0.75
180 Lost in translation--prognostic signatures for breast cancer. Nat Clin Pract Oncol 2008 0.75
181 The value of genomic analysis of breast cancer in drug development. J Natl Cancer Inst Monogr 2011 0.75
182 Paclitaxel-induced sickle cell crisis. Am J Health Syst Pharm 2008 0.75